MYC and malignant colon neoplasm: In colon cancer cell lines CT26 and HCT-116, AST treatment (50–100 μM; 24 h) transcriptionally repressed an oncogenic transcriptional factor, MYC, and thereby enhanced the expression of miR-29a-3p and miR-200a, which are known to exhibit an anti-metastatic effect [162].